Glaxo, Colgate seen bidding on Pfizer products

British drugmaker GlaxoSmithKline Plc and Colgate-Palmolive Co. are among companies expected to submit offers for Pfizer Inc’s array of consumer products in first-round bidding on Wednesday, the Wall Street Journal said.

New York-based Pfizer, the world’s largest drugmaker, is hoping to fetch about $14 billion for the products, the report said, citing people familiar with the situation.

The products include Bengay pain-relieving cream, Sudafed cold tablets and Listerine mouthwash.

Pfizer, which has steadily sold off parts of its operations to focus on its core drug business, acquired many of the consumer brands in its 2000 merger with rival U.S. drugmaker Warner-Lambert Co.

Pfizer said in February it aimed to sell or spin off its consumer products division, which had sales of $3.88 billion last year.

There was widespread speculation soon after the announcement that bidders could include Glaxo, which has a line of consumer products, and U.S.-based Colgate, which could market Listerine alongside its best-selling line of toothpastes.

For Subscribers

FOR SUBSCRIBERSAbdul El-Sayed tries to woo MAHA voters as Democrats seek inroads with RFK’s supporters

FOR SUBSCRIBERSKratom-like substances are popping up in a typically benign supplement

FOR SUBSCRIBERSGOP super PAC increases its spending for Sen. Jon Husted in tough Ohio race

FOR SUBSCRIBERSRecords reveal tumultuous marriage between slain New York Times executive and wife

FOR SUBSCRIBERSFrom clean energy warrior to ‘wall of shame,’ James Talarico reverses on a fossil fuel money pledge

FOR SUBSCRIBERSCongressional staff planned official trip with luxury stops in Italy and France weeks before election

FOR SUBSCRIBERSA harrowing ordeal aboard an Israel-bound plane

FOR SUBSCRIBERSOpenAI CEO Sam Altman to skip congressional hearing on rogue AI agents

FOR SUBSCRIBERSKey DOJ lawyers departed Trump ‘grand conspiracy’ probe amid pressure to produce, source says

FOR SUBSCRIBERSTrump’s new AI chatbot often links to a site launched under Clinton 26 years ago

FOR SUBSCRIBERSAt MAHA summit, industry CEOs the movement once vilified take the stage

FOR SUBSCRIBERSThis Paralympian has two goals: Win medals and give away $500,000 to her teammates

FOR SUBSCRIBERSCornell rape allegation spotlights stringent New York state laws that have long drawn criticism

FOR SUBSCRIBERSThe debate over AI’s future rages on both coasts

FOR SUBSCRIBERSDecades-old march dispute reignites in Northern Ireland, threatening political crisis

Colgate Chief Operating Officer Ian Cook told an investors’ conference earlier this month that Listerine was strategically right and that Colgate would look at buying the brand “very, very aggressively.”

For Subscribers

FOR SUBSCRIBERSAbdul El-Sayed tries to woo MAHA voters as Democrats seek inroads with RFK’s supporters

FOR SUBSCRIBERSKratom-like substances are popping up in a typically benign supplement

FOR SUBSCRIBERSGOP super PAC increases its spending for Sen. Jon Husted in tough Ohio race

FOR SUBSCRIBERSRecords reveal tumultuous marriage between slain New York Times executive and wife

FOR SUBSCRIBERSFrom clean energy warrior to ‘wall of shame,’ James Talarico reverses on a fossil fuel money pledge

FOR SUBSCRIBERSCongressional staff planned official trip with luxury stops in Italy and France weeks before election

FOR SUBSCRIBERSA harrowing ordeal aboard an Israel-bound plane

FOR SUBSCRIBERSOpenAI CEO Sam Altman to skip congressional hearing on rogue AI agents

FOR SUBSCRIBERSKey DOJ lawyers departed Trump ‘grand conspiracy’ probe amid pressure to produce, source says

FOR SUBSCRIBERSTrump’s new AI chatbot often links to a site launched under Clinton 26 years ago

FOR SUBSCRIBERSAt MAHA summit, industry CEOs the movement once vilified take the stage

FOR SUBSCRIBERSThis Paralympian has two goals: Win medals and give away $500,000 to her teammates

FOR SUBSCRIBERSCornell rape allegation spotlights stringent New York state laws that have long drawn criticism

FOR SUBSCRIBERSThe debate over AI’s future rages on both coasts

FOR SUBSCRIBERSDecades-old march dispute reignites in Northern Ireland, threatening political crisis

Glaxo Chief Executive Jean-Pierre Garnier said on Feb. 8 he would look at the Pfizer consumer healthcare business but there was no guarantee of a bid. A Glaxo spokesman declined to comment any further on Wednesday.

Colgate had no immediate comment on the newspaper report.

Industry analysts said other potential bidders could include Swiss drugmaker Novartis AG and Britain’s Reckitt Benckiser Plc , which was reported earlier this month to be lining up financing for a bid.